Tagged with A

Daiichi Sankyo Italy When you became President of Sankyo Pharma Italy in 2003 one of your objectives was to maximize sales of the existing portfolio- and the company’s sales have impressively tripled in this 5 years period. What have been the main guidelines of the Italian operations? Daiichi Sankyo Italy’s ability to brilliantly…

Assobiotec Biotechnologies have a significant role to play bringing Italy towards a more knowledge-based economy. What is the economic contribution of the sector today? According to the last Blossom Associati-Assobiotec report dedicated to biotechnologies in Italy, the sector’s turnover reaches approximately 5 billion Euros and represents 0,6% of the global Italian…

International Pharmaceutical Manufacturing Gr Although Indonesia in the last ten years had the second highest growth in ASIA in terms of drugs’ production and consumption, the market share of research based companies has dropped from 50% to 25%. What have been the main drivers leading to the current scenario? The share of international companies…

Parexel International Italy Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and which opportunities does the local environment provide to the group? The high number of clinical trials conducted in Italy every…

Mersifarma The Indonesian pharmaceutical market has gone through a series of developing phases which have ultimately led the domestic industry to gain the majority of the market share. In this respect what has been Mersi contribution to the development of the Indonesian pharmaceutical industry? My original vision for the company was…

Bausch & Lomb Germany With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities that no other company could thanks to its own transformations and special needs. Since Bausch&Lomb changed ownership in 2007, our…

Lundbeck South Korea What are the origins of Lundbeck in Korea and your involvement in its establishment? I joined Lundbeck just before it was officially established in Korea in April 2002. We started out as a small organization, working through our local partner Whanin. In October that same year we managed to launch…

Neurotech Pharmaceuticals What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when special new laws were passed by the Korean government aiming to get professors to contribute to the development of the…

generics “The ball is in the hands of the government,” according to Giorgio Foresti, general manager of Ratiopharm. “Once aware of the opportunities created by generics, politicians will have to make hard decisions.” Until now, generics prescriptions were limited by strong links between innovators and doctors, and price alignment trends reducing…

Korea   Already an economic powerhouse thriving on export-driven industries such as electronics, automotive and ship-building, South Korea is now looking to boost its potential in the life sciences and to move towards an innovation-based economy. Though it may traditionally be known in the West as ‘The Land of the Morning…

Brazil   With its huge market of 186 million people; its current position as the largest pharma market in Latin America, with strong growth projected; the influx of foreign and local investment into its pharma market; its reputation for conducting high-quality clinical research; and its incredible biological diversity, Brazil seems poised…

Russia   When the Russian Federation emerged from the former USSR in 1991 all the structures of the past social net that provided for the complete healthcare needs of citizens were just a memory of the past – nothing was left when the centralized distribution of medication of the former USSR…